Carregant...
Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2024-01-01
|
| Col·lecció: | Cancer Treatment and Research Communications |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2468294225000012 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|